Glow Blend
Glow · GLOW Stack
The Glow Blend is a three-peptide repair and anti-aging combination containing GHK-Cu (50mg), BPC-157 (10mg), and TB-500 (10mg). It builds on the Wolverine Blend foundation by adding GHK-Cu, a naturally occurring copper-complexed tripeptide that drives collagen remodeling and modulates approximately 4,000 human genes involved in tissue repair, anti-aging, and antioxidant defense. The name reflects the skin quality improvements users commonly report from the GHK-Cu component.
Starting dose. Per compound concentrations in vial (typically 0.5-1mg GHK-Cu + 100-500mcg BPC + 100-500mcg TB per injection)
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
How it works
The Glow Blend combines three distinct and complementary repair mechanisms:
GHK-Cu Component (50mg): Delivers bioavailable copper(II) to lysyl oxidase and other copper-dependent enzymes critical for collagen cross-linking, elastin formation, and extracellular matrix integrity. GHK-Cu directly modulates expression of approximately 4,000 genes, upregulating tissue repair genes (collagen, decorin, metalloproteinases) while suppressing inflammation and tissue destruction genes. It stimulates synthesis of collagen types I, III, and V, elastin, glycosaminoglycans, and proteoglycans. Also regulates copper-dependent antioxidant enzymes including superoxide dismutase.
BPC-157 Component (10mg): Activates local repair through VEGF-driven angiogenesis, nitric oxide system modulation, GH receptor upregulation, and FAK-paxillin pathway activation for cell migration. Creates the vascular infrastructure needed for repair.
TB-500 Component (10mg): Drives systemic repair via actin polymerization regulation, enabling fibroblasts and endothelial cells to migrate to injury sites. Suppresses NF-kB inflammatory signaling and promotes new blood vessel formation through pathways distinct from BPC-157.
Synergy: GHK-Cu provides the collagen remodeling template, BPC-157 builds the blood vessel network to supply it, and TB-500 delivers the repair cells. The combination addresses tissue repair from gene expression through structural assembly.
What to expect
Days 1-7: BPC-157 and TB-500 begin reducing inflammation and pain. GHK-Cu starts modulating gene expression and collagen synthesis pathways. Mild warmth at injection site is normal. Blue tint of reconstituted solution from copper is normal.
Weeks 2-4: Visible skin quality improvements from GHK-Cu collagen synthesis. BPC-157 angiogenesis and TB-500 cell migration producing measurable healing. Chronic injuries responding. Skin texture and elasticity improving. Hair may appear healthier.
Weeks 4-12: Full collagen remodeling effects from GHK-Cu. Organized collagen cross-linking via lysyl oxidase producing lasting structural improvements. Scar tissue reduction. Skin firmness and elasticity at peak improvement. Chronic joint and tendon issues substantially improved.
Evidence
Claims we could not support
No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.
Dose/route: Per compound concentrations in vial (typically 0.5-1mg GHK-Cu + 100-500mcg BPC + 100-500mcg TB per injection); SubQ injection. DRAW LAST when combining with other peptides.; Daily or 5 days on / 2 days off. No checked live PubMed abstract verified this exact displayed dose, route, and frequency for the same molecule/formulation and relevant population.
Mechanism: The Glow Blend combines three distinct and complementary repair mechanisms: GHK-Cu Component (50mg): Delivers bioavailable copper(II) to lysyl oxidase and other copper-dependent enzymes critical for collagen cross-linking, elastin formation, and extracellular matrix integrity. GHK-Cu directly modulates expression of approximately 4,000 genes, upregulating tissue repair genes (collagen, decorin, metalloproteinases) while suppressing inflammation and tissue destruction genes. It stimulates synthesis of collagen types I, III, and V, elastin, glycosaminoglycans, and proteoglycans. Also regulates copper-dependent antioxidant enzymes including superoxide dismutase. BPC-157 Component (10mg): Activates local repair through VEGF-driven angiogenesis, nitric oxide system modulation, GH receptor upregulation, and FAK-paxillin pathway activation for cell migration. Creates the vascular infrastructure needed for repair. TB-500 Component (10mg): Drives systemic repair via actin polymerization regulation, enabling fibroblasts and endothelial cells to migrate to injury sites. Suppresses NF-kB inflammatory signaling and promotes new blood vessel formation through pathways distinct from BPC-157. Synergy: GHK-Cu provides the collagen remodeling template, BPC-157 builds the blood vessel network to supply it, and TB-500 delivers the repair cells. The combination addresses tissue repair from gene expression through structural assembly.. No checked live PubMed abstract provided an exact-molecule/formulation sentence supporting this source-JSON mechanism claim.
Primary safety claim: No primary safety text present in source JSON. No checked live PubMed abstract directly verified this source-JSON safety claim at the displayed formulation, route, and regimen.
The honest take
GHK-Cu modulates 4,000 genes for anti-aging effects
The gene modulation data comes from validated microarray studies (Pickart et al.), but these are in vitro results. Whether injectable GHK-Cu achieves sufficient tissue concentrations to replicate this gene modulation systemically in humans is unconfirmed.
Topical GHK-Cu trials do show measurable skin improvements in 4-12 weeks. Injectable delivery may produce faster systemic effects, but this is extrapolated from topical data, not proven in injectable human trials.
Mechanistically sound - each peptide targets a distinct repair pathway (angiogenesis, cell migration, collagen remodeling). However, no study has tested this specific combination to confirm additive or synergistic benefit over any single component.
Interactions & stacking
Two different questions: what is documented about running these together, and what is documented about drawing them into the same syringe. A good pharmacological partner can still have to be pinned separately.
Documented together
Keep separate
Check any specific pair in the Stack & Interaction Checker, which answers both questions separately. Absence of a documented conflict is not evidence of safety.
Side effects & safety
Commonly reported
- Mild injection site redness or warmth (resolves in minutes)
- Temporary skin flushing from copper component
- Occasional lightheadedness post-injection
- Mild metallic taste reported by some users (copper-related)
Less common & notes
- Rarely reported: headache, transient nausea, localized copper skin staining at injection site (cosmetic, fades).
- GHK-Cu is an endogenous peptide present in human plasma, so adverse reactions are uncommon.
- Long-term safety data for the injectable combination in humans does not exist.
Pharmacokinetics
GHK-Cu: ~1 hour; BPC-157: ~2 min (rapid distribution); TB-500: ~2-3 hours
GHK-Cu: ~30 min; BPC-157: minutes (local); TB-500: 1-2 hours
GHK-Cu: ~6 hours; BPC-157: ~20 hours (activity); TB-500: ~12-16 hours
All components ~100% SubQ; GHK-Cu also effective topically
GHK-Cu: 12-24 hours (gene expression changes persist); BPC-157: 12-24 hours (VEGF/eNOS modulation); TB-500: 24-48 hours (actin effects)
Enzymatic degradation by peptidases. GHK-Cu copper released to ceruloplasmin/albumin pools. BPC-157 acid-stable. TB-500 cleared systemically.
Storage. Reconstitute with bacteriostatic water. Store refrigerated at 2-8 degrees C. Blue tint from copper ion is normal and does not indicate degradation. Shelf life approximately 28 days after reconstitution. Do not freeze after reconstitution. Protect from prolonged light exposure. Discard if cloudy, particulate, or color changes beyond normal blue tint.
Regulatory status
Not FDA-approved. Available through compounding pharmacies with prescription in some jurisdictions and through research chemical suppliers. Contains three research peptides. GHK-Cu has published human topical data but limited injectable clinical data. BPC-157 has FDA Orphan Drug Designation for short bowel syndrome. All current human use is experimental and off-label.
Put it to work
Calculate, log & track
Open Glow Blend straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open Glow Blend in the app →Go deeper
The guide & community
The complete Glow Blend walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗